1 unchanged sentence
Exhibit Title
+Added: Agreement and Plan of Merger, dated as of October 5, 2020, by and among BridgeBio Pharma, Inc., Eidos Therapeutic, Inc., Globe Merger Sub I, Inc.
+Added: and Globe Merger Sub II, Inc.
+Added: (incorporated by reference to Exhibit 2.1 to BridgeBio’s Current Report on Form 8-K filed with the SEC on October 6, 2020)
+Added: January 26, 2021
Amended and Restated Certificate of Incorporation of the Registrant, as currently in effect
Amended and Restated Bylaws of the Registrant, as currently in effect
+Added: November 6, 2020
Specimen Common Stock Certificate
1 unchanged sentence
Registration Rights Agreement, dated June 26, 2019, among the Registrant and certain of its stockholders
+Added: June 24, 2019
Indenture, dated as of March 9, 2020, by and between BridgeBio Pharma, Inc.
3 unchanged sentences
March 10, 2020
−Removed: Open Market Sale Agreement SM , dated as of July 7, 2020
−Removed: Agreement and Plan of Merger, dated as of October 5, 2020, by and among BridgeBio Pharma, Inc., Eidos Therapeutics, Inc., Globe Merger Sub I, Inc.
−Removed: and Globe Merger Sub II, Inc.
−Removed: O ctober 6, 2020
−Removed: Amended and Restated 2019 Employee Stock Purchase Plan, effective December 12, 2019
+Added: Indenture, dated as of January 28, 2021, by and between BridgeBio Pharma, Inc.
+Added: Bank National Association, as Trustee
+Added: January 29, 2021
+Added: Form of Global Note, representing BridgeBio Pharma, Inc.’s 2.50% Convertible Senior Notes due 2027
+Added: January 29, 2021
+Added: Purchase Agreement, dated January 25, 2021, by and among BridgeBio Pharma, Inc.
+Added: Morgan Securities LLC and Mizuho Securities USA LLC, as representatives of the several Initial Purchasers
+Added: January 25, 2021
+Added: Form of Confirmation for Capped Call Transactions
+Added: January 25, 2021
+Added: Sixth Amendment to the Loan and Security Agreement, between BridgeBio Pharma LLC and Hercules Capital, Inc., dated as of April 13, 2021
Filed herewith
+Added: Amended and Restated Employee Stock Purchase Plan
+Added: Filed herewith
Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
8 unchanged sentences
Filed herewith
−Removed: XBRL Instance Document
+Added: Inline XBRL Instance Document
Filed herewith
−Removed: XBRL Taxonomy Extension Schema Document
+Added: Inline XBRL Taxonomy Extension Schema Document
Filed herewith
−Removed: XBRL Taxonomy Extension Calculation Linkbase Document
+Added: Inline XBRL Taxonomy Extension Calculation Linkbase Document
Filed herewith
−Removed: XBRL Taxonomy Extension Definition Linkbase Document
+Added: Inline XBRL Taxonomy Extension Definition Linkbase Document
Filed herewith
−Removed: XBRL Taxonomy Extension Label Linkbase Document
+Added: Inline XBRL Taxonomy Extension Label Linkbase Document
Filed herewith
−Removed: XBRL Taxonomy Extension Presentation Linkbase Document
+Added: Inline XBRL Taxonomy Extension Presentation Linkbase Document
Filed herewith
+Added: Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101).
+Added: Filed herewith
This certification will not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section.
3 unchanged sentences
BridgeBio Pharma, Inc.
−Removed: November 5, 2020
/s/ Neil Kumar
2 unchanged sentences
(Principal Executive Officer)
−Removed: November 5, 2020
/s/ Brian Stephenson
1 unchanged sentence
Chief Financial Officer
−Removed: (Principal Financial Officer)
+Added: (Principal Financial Officer and Principal Accounting Officer)
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.